[{"indications": "Indications\u00a0\n(From Protein kinase inhibitors: British National Formulary)\nLapatinib, a tyrosine kinase inhibitor, is licensed for the treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2). It is indicated, in combination with capecitabine, for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab, or for postmenopausal women in combination with an aromatase inhibitor section 8.3.4.1.", "name": "LAPATINIB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.5 Other antineoplastic drugs", "Protein kinase inhibitors", "LAPATINIB"], "cautions": "Cautions\u00a0see section 8.1; low gastric pH (reduced absorption); susceptibility to QT-interval prolongation (including concomitant use of drugs that prolong QT-interval and electrolyte disturbances); monitor left ventricular function; monitor\r\nfor pulmonary toxicity; monitor liver function\r\nbefore treatment and at monthly intervals; interactions: Appendix 1 (lapatinib)", "side-effects": "Side-effects\u00a0see section 8.1; anorexia, diarrhoea (treat promptly),\r\ndecreased left ventricular ejection fraction, cardiac failure (fatal\r\ncases reported), malaise, rash, nail disorders, hyperbilirubinaemia,\r\nhepatotoxicity (discontinue permanently if severe); less commonly interstitial lung disease; respiratory failure (including fatal\r\ncases) also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201427.htm", "doses": ["In combination with capecitabine, adult over 18 years, 1.25\u00a0g once daily", "In combination with an aromatase inhibitor, adult over 18 years, 1.5\u00a0g once daily", "Always take at the same time in relation\r\nto food: either one hour before or one hour after food. Patients should\r\nreport unexpected changes in bowel habit"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk\u2014toxicity\r\nin animal studies; see also Pregnancy and Reproductive\r\nFunction"}]